Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Unger Takes Over ODE I As Acting Director; Temple To Focus On Clinical Science Role

30 Jan 2012

• By Derrick Gingery

Related Content

<i>Pradaxa</i> Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices

01 Apr 2011

FDA’s Temple Sees Sentinel As Important Tool For Confirming And Analyzing Drug Adverse Events

23 Jan 2012

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

14 Nov 2011

FDA, EMA Decisions On Avandia Reflect The Power Of REMS

27 Sep 2010

FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

19 Jul 2010

Related Companies

Boehringer Ingelheim GmbH

GSK plc

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.